Inhibrx Biosciences, Inc. reported $0 of revenue over the trailing twelve months, −100% on the year before. 7 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q2 2026). Net income: −$138M, trailing twelve months to Q2 2026. Free cash flow: −$132M, trailing twelve months to Q2 2026. EPS: −$8.88, trailing twelve months to Q2 2026.

INBXInhibrx Biosciences, Inc.

Healthcare

$95.10+245% 1Y

$95.10

$27.1252 weeks$141.84

INBX as reported

Inhibrx Biosciences, Inc. reported $0 of revenue over the trailing twelve months, −100% on the year before. 7 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q2 2026 · −100% against the twelve months before

Net income: −$138M
Net income · −16% year on year · trailing twelve months to Q2 2026
Free cash flow: −$132M
Free cash flow · −5.9% year on year · trailing twelve months to Q2 2026
EPS: −$8.88
EPS · −26% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for INBX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	−100%	Q2 2026
Net income	−$138M	−16%	Q2 2026
EPS	−$8.88	−26%	Q2 2026
ROE	−323%	n/a	Q2 2026
ROA	−86%	n/a	Q2 2026
ROIC	924%	n/a	Q2 2026
Free cash flow	−$132M	−5.9%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.